
|Articles|June 11, 2008
Dry AMD trial doses first patient
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
Advertisement
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
The trial, to determine safety, tolerability and pharmacokinetics of the oral treatment, is a single-site, double-masked, placebo-controlled, single ascending-dose study treating healthy subjects.
ACU-02 reduces the accumulation of A2E, thereby interrupting the pathophysiology of AMD and preserving retinal cells.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















